Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia (NCT07227818)
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy of NBI-1117568 in Preventing Relapse of the Symptoms of Schizophrenia and to Assess the Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia
🩺 Plain-English Summary (8th-Grade Level)
The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.
Who can join: Review the eligibility criteria below.
Location: Neurocrine Clinical Site — Garden Grove, California
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- Neurocrine Clinical Site — Garden Grove, California
- Neurocrine Clinical Site — La Habra, California
- Neurocrine Clinical Site — Lemon Grove, California
- Neurocrine Clinical Site — Oceanside, California
- Neurocrine Clinical Site — Torrance, California
- Neurocrine Clinical Site — West Hills, California
- Neurocrine Clinical Site — Hollywood, Florida
- Neurocrine Clinical Site — Maitland, Florida
- Neurocrine Clinical Site — Miami, Florida
- Neurocrine Clinical Site — Miami, Florida
- Neurocrine Clinical Site — Tampa, Florida
- Neurocrine Clinical Site — West Palm Beach, Florida
- Neurocrine Clinical Site — Atlanta, Georgia
- Neurocrine Clinical Site — Boston, Massachusetts
- Neurocrine Clinical Site — Flowood, Mississippi
- Neurocrine Clinical Site — Cedarhurst, New York
- Neurocrine Clinical Site — New York, New York
- Neurocrine Clinical Site — New York, New York
- Neurocrine Clinical Site — The Bronx, New York
- Neurocrine Clinical Site — Bellevue, Washington
📞 Contact the Study Coordinator
Phone: (877) 641-3461
Email: medinfo@neurocrine.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Schizophrenia
- Young Adults With Violent Behavior During Early Psychosis (Aim 2) — New York, New York
- Does tDCS Change Synaptic Density in the Brains of Patients With Schizophrenia — Toronto, Ontario
- Ketogenic Diet in People With Schizophrenia — Catonsville, Maryland
- Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia — Toronto, Ontario
- Investigating the Muscarinic System in Schizophrenia Using Positron Emission Tomography — Toronto, Ontario
- Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia — Suwanee, Georgia
Explore by condition: All Schizophrenia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.